Aurinia Pharmaceuticals Inc.

AUPH

Aurinia Pharmaceuticals Inc.

AUPH

Insider Sentiment (TTM):

Last Purchase:2026-06-02Last Sale:2025-08-01Shares Purchased (TTM):590,213Shares Sold (TTM):20,000

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:71,656,983Shares Outstanding:132,375,000Institutional Ownership Pct.:54.13%

Earnings Market Reaction:

Filing Date:2026-05-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	41	80	73	53	66	83	37	33	64	49	46	82
Debt Securities Current	338	318	279	262	246	275	312	297	255	302	292	269
Accounts And Other Receivables Net Current	49	41	31	40	40	37	36	26	29	24	38	19
Inventory Net	46	46	45	47	46	39	39	39	40	40	33	33
Prepaid Expense Current	-	-	-	-	-	-	-	8	8	9	16	11
Other Assets Current	2	1	0	1	1	1	3	7	2	1	2	1
Assets Current	480	492	439	409	406	447	440	410	398	425	426	416
Assets Noncurrent
Deferred Income Tax Assets Net	167	176	-	-	-	0	-	-	-	-	-	-
Finance Lease Right Of Use Asset	70	74	79	83	88	92	96	101	104	109	113	117
Finite Lived Intangible Assets Net	4	4	4	4	4	4	5	5	5	5	5	6
Operating Lease Right Of Use Asset	2	4	4	4	4	4	4	4	4	4	5	5
Property Plant And Equipment Net	2	2	2	2	3	3	3	3	3	3	3	4
Debt Securities Noncurrent	-	-	-	-	-	0	0	0	0	0	1	-
Other Assets Noncurrent	0	0	0	0	1	1	1	1	2	2	2	2
Assets	724	752	528	503	505	551	549	524	517	548	555	549
Liabilities And Stockhold…
Liabilities Current
Liabilities
Accounts Payable And Accrued Liabilities Current	-	-	-	-	-	-	57	56	50	54	52	41
Accounts Payable Current	3	3	2	3	4	5	-	-	-	4	-	-
Accrued Liabilities Current	58	67	50	50	42	65	-	-	-	50	-	-
Finance Lease Liability Current	17	17	16	16	15	14	15	14	14	15	13	14
Contract With Customer Liability Current	5	4	5	5	5	11	4	4	5	5	5	3
Operating Lease Liability Current	2	1	1	1	1	1	1	1	1	1	1	1
Other Liabilities Current	3	2	3	3	2	2	2	1	1	2	3	2
Liabilities Current	87	94	76	78	68	98	79	77	71	77	74	62
Liabilities Noncurrent
Finance Lease Liability Noncurrent	48	52	56	59	57	59	66	65	67	75	72	79
Other Liabilities Noncurrent	-	7	-	-	-	9	11	11	12	11	10	9
Contract With Customer Liability Noncurrent	-	13	-	-	-	2	-	-	-	-	-	-
Deferred Revenue Noncurrent	12	-	12	12	12	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	2	5	5	5	6	6	6	6	6	7	7	7
Liabilities	156	170	162	167	155	173	161	159	157	170	163	157
Stockholders Equity Inclu…
Common Stock Value Outstanding	1,087	1,120	1,117	1,123	1,163	1,188	1,207	1,206	1,208	1,200	1,199	1,196
Additional Paid In Capital Common Stock	97	111	110	105	101	127	120	112	105	121	110	99
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	-1	-1	-1	-1	-0	-1	-1	-1	-1	-1
Retained Earnings Accumulated Deficit	-615	-649	-860	-892	-913	-937	-938	-952	-953	-942	-915	-902
Stockholders Equity	568	581	366	335	350	377	388	365	359	378	392	392
Liabilities And Stockholders Equity	724	752	528	503	505	551	549	524	517	548	555	549
Related Party	-	-	-	-	-	0	0	0	1	1	-	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Issued	131	132	132	133	138	141	143	143	144	144	144	143
Shares Outstanding	131	132	132	133	138	141	143	143	144	144	144	143

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	1.25%	13.80%	1.39%	-	-	-	-	-	-	-	-	-
2025	0.86%	-6.53%	29.19%	32.72%	40.62%	24.93%	12.96%	13.88%	1.82%	0.36%	14.89%	9.38%
2024	0.77%	6.96%	7.54%	20.50%	28.34%	25.31%	6.24%	10.31%	-4.08%	11.79%	2.65%	8.48%
2023	-	-	-	-13.26%	-20.93%	-28.98%	16.37%	16.75%	1.52%	-9.80%	-16.11%	-15.28%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	5.55	5.25	5.76	5.23	5.93	4.57	5.60	5.33	5.60	5.50	5.77	6.75
Quick Ratio	5.01	4.76	5.17	4.63	5.26	4.17	5.11	4.72	4.94	4.87	5.11	6.02
Working Capital	393.69M	398.24M	362.52M	330.70M	337.36M	348.83M	361.85M	332.76M	327.17M	347.61M	352.58M	354.25M
Leverage & Debt
Debt to Equity	0.28	0.29	0.44	0.50	0.44	0.46	0.42	0.44	0.44	0.45	0.42	0.40
Interest Coverage TTM	29.12	24.23	15.81	11.46	6.58	-0.97	-6.54	-11.69	-18.57	-13.92	-11.01	-10.10
Debt Ratio	0.22	0.23	0.31	0.33	0.31	0.31	0.29	0.30	0.30	0.31	0.29	0.29
Efficiency & Turnover
Asset Turnover TTM	0.49	0.43	0.49	0.51	0.48	0.43	0.40	0.39	0.40	0.34	0.30	0.31
Per Share Metrics
Diluted EPS TTM	2.17	2.07	0.57	0.44	0.28	0.04	-0.15	-0.35	-0.43	-0.54	-0.54	-0.51
Free Cash Flow Per Share TTM	1.26	1.01	0.91	0.69	0.46	0.31	0.20	-0.01	-0.14	-0.24	-0.26	-0.28
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	89.74%	88.46%	88.93%	89.51%	88.24%	87.99%	87.25%	86.08%	88.78%	91.94%	93.63%	96.38%
Operating Profit Margin TTM	41.73%	37.06%	26.34%	19.99%	12.30%	-1.99%	-14.84%	-29.31%	-39.37%	-52.24%	-56.73%	-52.06%
Net Profit Margin TTM	99.97%	101.47%	29.28%	23.31%	16.11%	2.45%	-10.23%	-24.31%	-32.69%	-44.45%	-48.59%	-45.42%
Growth Metrics
Net Revenue Growth (1Y)	20.62%	20.38%	20.62%	25.59%	29.20%	33.97%	38.72%	29.35%	30.37%	30.95%	23.14%	82.19%
Net Income Growth (1Y)	648.43%	4,893.08%	-445.14%	-220.43%	-163.69%	-107.37%	-70.78%	-30.78%	-35.34%	-27.88%	-33.14%	-53.59%
EPS Growth (1Y)	685.42%	5,216.00%	-474.58%	-227.98%	-166.02%	-107.38%	-70.83%	-31.04%	-35.96%	-28.54%	-33.61%	-53.93%
Valuation Metrics
P/E TTM	6.58	7.46	18.71	18.84	28.03	223.34	-46.50	-16.25	-11.53	-16.50	-14.38	-19.00
P/B TTM	3.46	3.69	3.98	3.41	3.19	3.40	2.70	2.24	2.01	3.41	2.83	3.52
P/S TTM	6.58	7.57	5.48	4.39	4.52	5.46	4.76	3.95	3.77	7.34	6.99	8.63
Market Cap	1.96B	2.14B	1.46B	1.14B	1.12B	1.28B	1.05B	818.40M	721.51M	1.29B	1.11B	1.38B
Enterprise Value	1.99B	2.13B	1.46B	1.16B	1.12B	1.27B	1.09B	863.82M	738.79M	1.33B	1.15B	1.39B
Calculated Values
Free Cash Flow TTM	166.92M	135.66M	120.10M	92.56M	64.07M	44.16M	28.36M	-1.84M	-20.48M	-33.70M	-37.56M	-39.62M
Net Debt	23.69M	-11.37M	-1.15M	22.45M	4.91M	-10.83M	43.74M	45.42M	17.29M	41.21M	39.12M	11.73M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-02Purchase

Owner: Tang, Kevin, Tang Capital…

Title: Chief Executive Officer

Shares: 206,005

Price/Share: $15.28

Value: $3,147,756.40

Shares Owned: 13,044,106

Relationship: TenPercentOwner

Ownership: Indirect

2026-03-03Purchase

Owner: Tang, Kevin

Title: -

Shares: 184,208

Price/Share: $14.22

Value: $2,619,437.76

Shares Owned: 12,229,500

Relationship: Director

Ownership: Indirect

2025-08-05Purchase

Owner: Tang, Kevin

Title: -

Shares: 200,000

Price/Share: $11.68

Value: $2,336,000.00

Shares Owned: 11,329,500

Relationship: Director

Ownership: Indirect

2025-08-01Sale

Owner: Keenan, Greg

Title: Chief Medical Officer

Shares: 20,000

Price/Share: $10.50

Value: $210,000.00

Shares Owned: 133,484

Relationship: Officer

Ownership: Direct

2025-03-07Sale

Owner: Keenan, Greg

Title: Chief Medical Officer

Shares: 8,305

Price/Share: $8.23

Value: $68,350.15

Shares Owned: 153,484

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-02	Tang, Kevin, Tang Capital…	TenPercentOwner	Chief Executive Officer	Indirect	Purchase	206,005	15.28	$3,147,756.40	13,044,106	4
2026-03-03	Tang, Kevin	Director	-	Indirect	Purchase	184,208	14.22	$2,619,437.76	12,229,500	4
2025-08-05	Tang, Kevin	Director	-	Indirect	Purchase	200,000	11.68	$2,336,000.00	11,329,500	4
2025-08-01	Keenan, Greg	Officer	Chief Medical Officer	Direct	Sale	20,000	10.50	$210,000.00	133,484	4
2025-03-07	Keenan, Greg	Officer	Chief Medical Officer	Direct	Sale	8,305	8.23	$68,350.15	153,484	4
2025-03-04	Miller, Joseph M	Officer	Chief Financial Officer	Direct	Sale	56,154	7.92	$444,739.68	577,361	4
2025-03-04	Tang, Kevin	Director	-	Indirect	Purchase	748,038	8.00	$5,984,304.00	10,029,500	4
2025-03-04	Greenleaf, Peter	Director,Officer	Chief Executive Officer	Direct	Sale	164,947	7.92	$1,306,380.24	1,788,945	4
2025-03-04	Donley, Matthew Maxwell	Officer	Chief Operating Officer	Direct	Sale	58,991	7.92	$467,208.72	680,465	4
2025-03-04	Robertson, Stephen P.	Officer	EVP, General Counsel	Direct	Sale	57,607	7.92	$456,247.44	509,276	4
2025-03-03	Keenan, Greg	Officer	Chief Medical Officer	Direct	Sale	12,239	8.00	$97,912.00	161,789	4
2024-12-09	Tang, Kevin	Director	-	Indirect	Purchase	500,000	9.09	$4,545,000.00	8,429,500	4
2024-11-11	Bailey, Jeffrey Allen	Director	-	Direct	Sale	4,557	8.43	$38,415.51	13,356	4
2024-11-11	Smith, Karen L.	Director	-	Direct	Sale	5,241	8.43	$44,181.63	12,672	4
2024-08-06	Habig, Scott Michael	Officer	Chief Commercial Officer	Direct	Sale	18,249	5.31	$96,902.19	456,338	4
2024-05-21	Mackay-Dunn, R. Hector	Director	-	Direct	Sale	5,630	5.74	$32,316.20	18,595	4
2024-05-21	Balakrishnan, Brinda	Director	-	Direct	Sale	520	5.74	$2,984.80	17,523	4
2024-05-21	Billen, Daniel	Director	-	Direct	Sale	5,252	5.74	$30,146.48	28,141	4
2024-05-21	Leversage, Jill	Director	-	Direct	Sale	5,610	5.74	$32,201.40	12,918	4
2024-05-21	Jayne, David R.W.	Director	-	Direct	Sale	4,946	5.74	$28,390.04	44,364	4
2024-03-06	Donley, Matthew Maxwell	Officer	EVP, Ops & Strategy	Direct	Sale	40,665	5.51	$224,064.15	584,072	4
2024-03-06	Greenleaf, Peter	Director,Officer	Chief Executive Officer	Direct	Sale	126,981	5.60	$711,093.60	1,522,114	4
2024-03-06	Habig, Scott Michael	Officer	Chief Commercial Officer	Direct	Sale	17,777	5.60	$99,551.20	474,587	4
2024-03-06	Miller, Joseph M	Officer	Chief Financial Officer	Direct	Sale	34,811	5.60	$194,941.60	495,928	4
2024-03-06	Robertson, Stephen P.	Officer	EVP, General Counsel	Direct	Sale	57,745	5.60	$323,372.00	443,824	4
2024-02-27	Knappertz, Volker	Officer	EVP, Research and Development	Direct	Sale	4,930	6.10	$30,073.00	319,128	4
2024-02-20	Habig, Scott Michael	Officer	Chief Commercial Officer	Direct	Sale	15,867	5.48	$86,951.16	492,364	4
2024-02-20	Knappertz, Volker	Officer	EVP, Research and Development	Direct	Sale	25,146	5.48	$137,800.08	324,058	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

54.13%

Inst. Shares: 71,656,983

Shares Outstanding: 132,375,000

2025-12-31

52.60%

Inst. Shares: 70,675,417

Shares Outstanding: 134,367,000

2025-09-30

49.15%

Inst. Shares: 64,778,750

Shares Outstanding: 131,808,000

2025-06-30

41.55%

Inst. Shares: 56,038,679

Shares Outstanding: 134,873,000

2025-03-31

43.08%

Inst. Shares: 59,850,609

Shares Outstanding: 138,917,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	71,656,983	132,375,000	54.13%
2025-12-31	70,675,417	134,367,000	52.60%
2025-09-30	64,778,750	131,808,000	49.15%
2025-06-30	56,038,679	134,873,000	41.55%
2025-03-31	59,850,609	138,917,000	43.08%
2024-12-31	56,362,200	143,057,000	39.40%
2024-09-30	55,715,642	143,051,000	38.95%
2024-06-30	54,396,680	143,327,000	37.95%
2024-03-31	53,495,497	144,013,000	37.15%
2023-12-31	51,973,907	143,236,000	36.29%
2023-09-30	47,078,204	142,847,000	32.96%
2023-06-30	45,962,124	142,777,000	32.19%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Aurinia Pharmaceuticals Inc. (AUPH) — SEC Financial Statements & Analysis

Aurinia Pharmaceuticals Inc. (AUPH) is a pharmaceutical preparations company. Aurinia Pharmaceuticals Inc. trades on AUPH: Nasdaq as: AUPH. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Aurinia Pharmaceuticals Inc. reported a 20.62% year-over-year revenue growth, a Gross Profit Margin of 89.74% (TTM), a Debt-to-Equity ratio of 0.28x, a Price-to-Sales (P/S) ratio of 6.58x (TTM), a Price-to-Book (P/B) ratio of 3.46 (TTM), at a market cap of $1.96B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 20.62%
Gross Profit Margin TTM: 89.74%
Debt To Equity: 0.28x
P/S TTM: 6.58x
P/B TTM: 3.46
Market Cap: $1.96B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Aurinia Pharmaceuticals Inc. in?

Aurinia Pharmaceuticals Inc. (AUPH) operates in the Pharmaceutical Preparations industry.

What is AUPH's market cap?

Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalization of $1.96B as of 2026-03-31.

What is AUPH's P/E ratio?

Aurinia Pharmaceuticals Inc. (AUPH)'s trailing twelve month P/E ratio is 6.58x as of 2026-03-31.

What exchange does AUPH trade on?

Aurinia Pharmaceuticals Inc. (AUPH) trades on the AUPH: Nasdaq.

Aurinia Pharmaceuticals Inc. (AUPH) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.